Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» AbbVie
AbbVie
AAN 2023: AbbVie highlights Qulipta’s edge over oral migraine prophylaxis
Clinical Trials Arena
Wed, 04/26/23 - 10:05 am
AbbVie
Qulipta
chronic migraine
Big pharma holds steady on research spending
EP Vantage
Fri, 04/21/23 - 10:03 am
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Big pharma’s biggest spenders revealed: 2022 edition
EP Vantage
Fri, 04/21/23 - 10:00 am
M&A
R&D
AbbVie
AstraZeneca
Bristol Myers Squibb
Eli Lilly
GSK
JNJ
Merck
Novartis
Pfizer
Roche
Sanofi
FDA expands Qulipta indication to include chronic migraine prevention
Healio
Tue, 04/18/23 - 10:13 pm
AbbVie
migraine
FDA
CGRP blockers
Qulipta
In upcoming skin disease clash, doctors see Novartis' Cosentyx as an underdog
Fierce Pharma
Tue, 04/11/23 - 10:04 am
Novartis
Cosentyx
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
AbbVie-sponsored docuseries goes beyond the before and after
Medical Marketing and Media
Mon, 04/10/23 - 04:55 pm
AbbVie
pharma marketing
plastic surgery
aesthetics
AbbVie removes two approvals for blood cancer drug Imbruvica
BioPharma Dive
Fri, 04/7/23 - 01:49 pm
AbbVie
Imbruvica
cancer
AbbVie knocks down earnings forecast due to IPR&D charge
Fierce Biotech
Thu, 04/6/23 - 11:54 am
AbbVie
R&D
Spotlight – following Humira in hidradenitis suppurativa
EP Vantage
Tue, 04/4/23 - 10:10 am
AbbVie
Humira
hidradenitis suppurativa
UCB Pharma
Bimzelx
MoonLake Immunotherapeutics
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
FDA
AbbVie
Alvotech
Ascendis Pharma
Astellas
AstraZeneca
Biogen
Daiichi Sankyo
Eli Lilly
Ferring Pharmaceuticals
Hugel
Innoviva
Ionis Pharmaceuticals
Lundbeck
Merck
Novo Nordisk
Otsuka
Pfizer
Roche Seagen
Seres Therapeutics
Takeda
UCB
Vertex Pharmaceuticals
This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie
Motley Fool
Fri, 03/31/23 - 10:16 am
Skyrizi
AbbVie
clinical trials
ulcerative colitis
AbbVie sidelines CytomX after seeing midphase oncology ADC data, opens talks on returning lead drug
Fierce Biotech
Tue, 03/28/23 - 10:22 am
AbbVie
CytomX Therapeutics
cancer
oncology
antibody-drug conjugate
Top 10 pharma R&D budgets in 2022
Fierce Biotech
Mon, 03/27/23 - 10:21 pm
R&D
Roche
JNJ
Merck
Pfizer
Novartis
AstraZeneca
Bristol Myers Squibb
Eli Lilly
Sanofi
AbbVie
AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus
BioSpace
Fri, 03/24/23 - 11:50 am
AbbVie
Skyrizi
ulcerative colitis
lupus
Rinvoq
clinical trials
AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda
Fierce Pharma
Thu, 03/23/23 - 11:39 am
AbbVie
Skyrizi
IBD
ulcerative colitis
clinical trials
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
EP Vantage
Tue, 03/21/23 - 09:54 am
AAD
hidradenitis suppurativa
AbbVie
Humira
UCB Pharma
Bimzelx
Acelyrin
izokibep
AbbVie’s Skyrizi hits the spot in refractory psoriasis
Pharmaphorum
Mon, 03/20/23 - 11:21 am
AbbVie
Skyrizi
psoriasis
AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate
Fierce Pharma
Wed, 03/15/23 - 11:25 am
Pfizer
AbbVie
Humira
drug pricing
inflation
AbbVie braces for 'greater erosion' of Humira franchise in second half of this year
Endpoints
Tue, 03/7/23 - 10:22 pm
AbbVie
Humira
Rinvoq
AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff
Fierce Pharma
Tue, 03/7/23 - 11:55 am
AbbVie
Pharma CEOs
executive pay
Humira
Richard Gonzalez
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »